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Israel: Bioethics in a Jewish-Democratic State
MICHAEL L. GROSS and VARDIT RAVITSKY

Unlike most Western nations, Israel does not recognize full separation of
church and state but seeks instead a gentle fusion of Jewish and democratic
values. Inasmuch as important religious norms such as sanctity of life may
clash with dignity, privacy, and self-determination, conflicts frequently arise as
Israeli lawmakers, ethicists, and healthcare professionals attempt to give substance to the idea of a Jewish-democratic state. Emerging issues in Israeli
bioethics — end-of-life treatment, fertility, genetic research, and medical ethics
during armed conflict — highlight this conflict vividly.

The Right to Die
A patient’s right to control life-sustaining treatment is no longer controversial
in Western Europe and the United States. Following an intense debate that
began with a terminally ill patient’s right to refuse extraordinary lifesaving
care, patients’ rights moved quickly to encompass a competent, incompetent, or
never-competent patient’s right to withhold or withdraw ordinary, extraordinary, and/or basic care. In most Western nations, chronically ill patients enjoy
the same rights as terminally ill patients in this regard.
The situation in Israel is much different. A 1996 patients’ rights law 1 pointedly excludes any mention of a patient’s right to die with dignity, and criminal
law forbids any action that “accelerates” a patient’s death. In this atmosphere,
the courts have been reluctant to affirm any but the simplest requests of
competent, terminally ill patients to refuse ventilator support on the grounds
that these are extraordinary, heroic, and probably futile measures. In exceptional cases, district courts have permitted physicians to remove life support
from a once-competent patient who was careful to document his intentions
well before losing consciousness.2
These rulings are rare, however, trying to knit together recent Israeli legislation affirming respect for human dignity with long-standing arguments from
American bioethics that refute the distinction between withholding and withdrawing treatment. Apart from these exceptions, patients in Israel do not enjoy
the right to withdraw treatment. The effects of this policy are problematic.
Permanent vegetative state (PVS) patients linger, end-state cancer patients
cannot end their lives with dignity, and failure to allow parents of critically ill
neonates to withdraw treatment spurs late-term abortion.
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In light of growing concern and lack of coherent policy, Israel’s health
minister established a public committee in 2000 to formulate guidelines for
end-of-life care — that is, for terminally ill patients with a remaining life span of
6 months or less. Their mandate excluded chronically ill patients with minimal
hope of recovery (e.g., patients in a permanent vegetative state). In spite of
dissenting opinions, this multidisciplinary committee sought consensus rather
than confrontation as it wrestled with religious and democratic imperatives. In
general, the final recommendations walk a fine line between the demands of
autonomy-based secular bioethics and religious norms granting great weight to
the sanctity of life.
Apart from establishing guidelines for palliative care and advance directives,
the proposed law contends with a patient’s right to forego treatment.3 Although
it stipulates that no patient can be treated without informed consent, the law
prohibits termination of “continuous” treatment — that is, any form of care that
is essentially uninterrupted and admits of no clear distinction between the end
of one cycle and the beginning of another. The prime example is mechanical
ventilation. Continuous care contrasts with “discrete” care, which does begin
and end in well-defined cycles. Thus, the kinds of care a patient may withdraw
are limited. Nor is the right to refuse care absolute. Although the proposed law
allows competent patients to refuse food and fluids, it prevents surrogate
decisionmakers from exercising the same right on behalf of incompetent patients.
And whereas incompetent patients may refuse basic care by advance directive,
physicians may only honor their request when death is imminent and the
failure to provide food and fluids will not shorten a patient’s expected life
span. Recommendations for end-of-life neonatal care are equally contentious.
Although the current draft law does not yet address neonatal care, preliminary
guidelines stipulate that neonates less than 25 weeks old must be resuscitated
and treated with the full complement of available care unless the statistical rate
of survival is less than 5%. Infants whose gestational age is greater than 25
weeks must be provided with vigorous care, including resuscitation, even
when they show no signs of life.
Key features of the Israeli debate depart from currently well accepted
bioethical norms in most Western countries. Disagreement led the committee
to defer a decision about including PVS and other chronically ill patients in
the draft legislation. In the meantime, this is a significant exclusion. Failure
to consider PVS patients, an important class of patients who retain the right
to terminate life support, violates principles of equality and autonomy, ignores the cost of continued futile care, and may offend human dignity. In
response to the neonatal guidelines, the Israeli Society of Neonatalogists
asked why infants over 25 weeks enjoy special status, how doctors can
reasonably evaluate statistical survival rates during a difficult delivery, and
why physicians are obligated to resuscitate and treat certain classes of newborns when it may be against their better judgment and the best interests of
the neonate to do so.
Moreover, the underlying logic is, within the context of Western bioethics, no
longer compelling. The distinction between continuous and discrete care, for
example, calls to mind the animated ruling of Barber v. Los Angeles County,
whose presiding judge reminded us that “each pulsation of the respirator or
each drop of fluid introduced into the patient’s body by intravenous feeding
devices is comparable to a manually administered injection or item of medica248
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tion.” 4 The argument was important in 1983, enabling one to see that withdrawing treatment, a contentious idea at the time, is nothing more than
refusing treatment, a well-founded moral and legal right. Since then, the
distinction between refusing treatment and refusing to continue treatment has
largely disappeared and no longer carries ethical and legal weight in the
United States and in Europe.
In Israel, however, the distinctions between withholding and withdrawing,
ordinary and extraordinary care, continuous and discrete treatment, and terminally ill and PVS patients remain important. Fear of the slippery slope is one
reason why this is so. Given wariness of developments in the United States and
Europe, it may make sense to draw the line at terminally ill rather than PVS
patients to avoid mistreating chronically ill incompetent patients and to arrest
the slide toward physician-assisted suicide (PAS) or physician-assisted death
(PAD). Thus, the proposed legislation explicitly forbids PAS and PAD and only
respects the wishes of competent or once-competent terminally ill patients with
advance directives.
Beyond the slippery slope, however, one must also consider the prevailing
influence of Orthodox Jewish norms in Israel. PVS patients and neonates merit
vigorous treatment because of the overriding duty to offer medical care to any
human being. Terminally ill patients represent a special class of carefully
defined exclusions in Orthodox Jewish law (Halacha). Within this class, treatment options are limited. One may withhold treatment but must be careful to
avoid any hint that one is actually taking a patient’s life. Hence the distinction
between continuous and discrete care. Whereas a patient may refuse the latter,
physicians are prohibited from withdrawing continuous care, so as to avoid an
active intervention that hastens a patient’s death. This prohibition, therefore,
seriously obstructs a patient’s right to die. Although the Barber Court resolved
this dilemma with a clever linguistic argument, Israeli bioethicists looked to a
mechanical solution: intricate “timers” to turn off ventilators at certain intervals
to transform continuous care into discrete treatment. These devices may successfully bridge secular and religious interests.
If secular bioethicists accommodated religious interests by deferring discussion of PVS patients, agreeing to timers, and accepting limitations on a patient’s
right to refuse treatment, advocates of traditional Jewish norms made concessions of their own. Not all rabbinic authorities support advance directives,
arguing instead that no directive beyond Jewish law can govern decisionmaking. Others strongly believe that there are never grounds for withholding food
and fluids — an act tantamount to assisted suicide. In the process of forging a
consensus, however, these reservations were put aside as the committee formulated its guidelines.
Patient rights at the end of life offer a challenge to any nation grappling with
democratic and religious norms. Unlike Western nations that must sometimes
seek compromise with powerful religious interests, the imperative to synthesize secular and traditional values in Israel is as important for national identity
as it is for political stability. Many attempts to reconcile, let alone unite, these
two disparate sets of values have come up empty, and whereas some feel that
the law is a compromise, each side gaining and losing (some more than others),
others are convinced that its novelty paves the way for a genuine consensus
and successful integration of Jewish and democratic values. Similar efforts
infuse the debate over genetics and fertility.
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Population Genetics, Stem Cell Research, and Fertility Treatment
Dilemmas of Population Genetics
Efforts by private companies to collect DNA samples from Jews of Eastern
European descent (Ashkenazi) for mapping and identifying genes associated
with such diseases as diabetes, heart disease, and Alzheimer’s generate considerable controversy in Israel. These companies are gradually creating a
“private genetic databank,” and although patients sign an informed consent
form allowing their unidentified DNA to be used in research, there is some
concern that data may later be sold to drug companies outside of Israel for
further research without patients realizing that the data have been resold.
This raises significant ethical issues. First, the company’s intention to “export”
the genetic data risks loss of what some consider a “national resource.” Second,
the research may stigmatize the Ashkenazi Jewish community by revealing
predispositions to certain diseases and thereby leading to discrimination by
employers and insurance providers. Third, the source of genetic information is
unidentifiable. Without any way to track the donor, patients may be denied
future medical and pharmacological benefits. Finally, genetic research generates
conflicts of interest because private companies pay physicians significant fees
($50 per sample), which may lead patients to question the integrity of physicians who propose participation in research. These questions are prompting
preliminary attempts at regulation and legislation, particularly as interest in
population genetics is likely to grow in light of the large variety of ethnic
groups available for research in Israel today.
Embryonic Stem Cells Research
In 1999, Israeli lawmakers created a 5-year moratorium on cloning and germline gene therapy to study the ethical, legal, social, and scientific ramifications
of these technologies.5 This law bans in utero implantation of blastocysts
created by cloning but does not address nonreproductive cloning for research
purposes. In 2001, a bioethics advisory committee considered the issues further.6 In view of the tremendous potential benefits of stem cell research, the
committee asked whether it is ethically acceptable to extract embryonic stem
(ES) cells from a human embryo prior to its implantation in utero (thereby
ending its potential development) to cultivate and study these cells in the
laboratory. To answer this question, the committee examined how different
religious traditions define and categorize the embryo at its different developmental stages. In contrast to the Catholic view,7 which treats the embryo as a
person from the moment of conception, Jewish and Muslim traditions see an
embryo that progressively acquires human status during embryonic development. According to the Orthodox Jewish view, genetic materials outside the
uterus have no legal status because they are not considered part of a human
being until implantation. Therefore, the status of the preimplantation embryo
outside the womb is comparable to that of gametes — namely, it should not be
wasted but may be manipulated for therapeutic purposes.
Based on traditional Jewish guidelines, the committee’s recommendations
allow the donation of excess embryos from IVF (prior to implantation) for
therapeutic research, provided parental donors give informed consent and the
medical team performing the IVF is distinct from the research team using the
250
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ES cells. However, researchers may not create embryos from gamete donors for
any reason other than implantation. These embryos may be used for research
only when parents choose not to implant them. Although preembryos are not
considered human beings, there is concern that creating embryos from gamete
donors for the sole purpose of research may offend donors, lead to the abuse
and commercialization of gamete donations, and, more generally, cause the
public to fear that IVF technology is being misused. Researchers may, however,
clone embryos for research because cloned embryos, like excess embryos, have
no potential to become human beings, given that their implantation is prohibited under current Israeli law.
Relative to other countries, guidelines for genetic research in Israel allow
researchers considerable freedom. Israelis tend to trust new technology and
rapidly embrace the benefits it offers. This tendency is partly attributable to a
religious tradition that ascribes overriding value to any attempt to cure and
save lives and underlies open-minded attitudes toward research efforts that
have therapeutic aims. Moreover, Jewish values do not regard human efforts to
intervene in nature as an assault on divine will but rather as an appropriate use
of the powers with which God endowed mankind. Contrary to the understanding expressed in the Universal Declaration on the Human Genome and Human
Rights,8 therefore, reproductive cloning is not necessarily perceived as an
affront to human dignity. For this reason, the United Nations’ “International
Convention against the Reproductive Cloning of Human Beings” poses an
interesting challenge for Israel. Although it wishes to contribute to international efforts to control what is now a medically and ethically unsafe method
of reproduction, Israel, as a Jewish state, cannot support limitations on cloning
for therapeutic research and will be reluctant to support a ban on reproductive
cloning if the sole objection is built on the belief that cloning offends human
dignity.
Fertility and Parenthood
Because of a unique combination of historical, cultural, legal, and economic
factors, bioethical issues surrounding fertility are very salient in Israel. Female
barrenness is a consistent motif in the Bible, and the desire for biological
offspring — “Be fruitful and multiply” — is a profound element of Jewish tradition. The perception of infertility as a “curse” and of fertility as a “blessing”
pervades Israeli culture, where community life is centered on children.9 The
historical trauma of the Holocaust and the demographic imbalance between
Arabs and Jews in the region fuel concerns that the very future of the Jewish
people is threatened. These fears further encourage an official pronatalist
population policy and a birth rate that is double the average of most European
countries.10
Israel’s pronatalist policy is evident in every aspect of its legal and regulatory
framework. Incremental social security benefits for each child encourage large
families. State-funded healthcare covers pregnancy and birth-related expenses
but not contraception. National health insurance also covers infertility treatment (including IVF) to enable couples without children from their current
marriage to have a first and second child, and to treat childless women who
wish to establish a single-parent family. This level of public funding is unparalleled in any other country in the world. Moreover, labor laws compensate
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working women for absences resulting from infertility treatment. As a result,
Israel has the highest rate of consumption of IVF in the world.11
The legal system also demonstrates a strong bias in favor of reproduction. In
the precedent-setting Nakhmani case,12 an estranged couple that had previously
undergone IVF fought over the disposition of the frozen embryos. The woman
wanted to implant the embryos in a surrogate to have a genetic child of her
own, but the hospital refused to release the embryos without the genetic
father’s consent.13 Construing the case as a conflict between a woman’s “right
to motherhood” and a man’s “right to nonfatherhood,” the Supreme Court
ruled in favor of motherhood, thus acknowledging a right that imposes a
correlative duty on the father.
Israel’s surrogacy law is similarly pronatal. In 1996, Israel was the first
country in the world to enact a law to regulate and give legal validity to
surrogacy agreements.14 The law requires approval of all surrogacy agreements
by a special statutory committee. The child’s status is carefully delineated,
giving the “intended parents” custody at birth and guaranteeing their status as
the “exclusive parents and guardians of the child.” The surrogate mother’s
wish to withdraw from the agreement and/or gain custody requires court
approval based on a justifying change in circumstance and a reasonable
expectation that the child’s best interest will not be harmed. As of March 2002,
104 agreements were approved (of 150 requests), and 44 children were born of
33 deliveries.
With nearly 2000 women awaiting donation in Israel today, another impediment to fertility is a severe shortage of donor eggs. Until recently, only women
undergoing fertility treatments could donate their excess eggs. In 2001, the
Minister of Health allowed doctors to implant eggs harvested and fertilized
outside of Israel, thereby meeting the growing demand by what may be called
“egg import.” Further proposals include legislation that will expand the possible circle of donors by allowing altruistic (i.e., unpaid) donations from
women who are not undergoing treatment themselves.
Whereas the strong pronatalist atmosphere in Israel explains free and
unimpeded access to generous fertility treatment, it also raises serious ethical
difficulties. Some bioethicists claim that this cultural atmosphere imbued with
pronatalism encourages individuals to overconsume reproductive technologies,
creates a “national obsession” with biological parenthood, and raises questions
about the indoctrination of women toward motherhood at all costs.15 In most
cases, the healthcare system does not provide support systems for failed
treatment or for discussion of alternatives such as adoption or voluntary
childlessness, an option that is virtually unheard of in Israel. Moreover, public
funding of fertility treatment prompts serious questions about equity and
access in healthcare as economic constraints now force Israelis to consider the
urgency of rationing basic and life-saving services. Lifesaving services also
emerge in an entirely different context as we consider medical ethics and
armed conflict.
Medical Ethics in Armed Conflict
Following the outbreak of violence between Israelis and Palestinians in October
2000, Israeli military planners found themselves struggling to contain terror
while, at the same time, ensuring, among other things, unimpeded access to
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medical care in the occupied territories. But this proved difficult to achieve.
Blockading Palestinian cities to prevent terrorism caused severe hardship
among the local civilian population and disrupted access to medical care.
During combat, Palestinians claimed that Israeli soldiers attacked clearly marked
ambulances, killed medical personnel, and obstructed the evacuation of wounded
militiamen and civilians.
Prior to March 2002, Israel made no attempt to reoccupy Palestinian cities
and largely refrained from entering Palestinian-controlled territory. Israel did,
however, blockade Palestinian cities from time to time to disrupt communication between terrorist cells. Regardless of its efficacy, the policy wreaks havoc
on the civilian population. Troops stationed around major population centers
slow traffic as they check ID cards and search residents. Many are turned back
at roadblocks, and entire villages are cut off from one another. Physical
obstructions, concrete blocks, trenches, and pits make internal movement
difficult, as do frequent curfews and closures.
These disruptions hinder access to medical care. B’Tselem, the Israeli Information Center for Human Rights in the Occupied Territories, cites an appeal by
the Palestinian Red Cross to Israel’s High Court of Justice in February 2001 on
behalf of 121 sick or wounded patients whose transportation to medical
facilities was delayed. Their report reiterates concern voiced by the International Committee of the Red Cross (ICRC) that the failure to provide timely
treatment aggravates individual medical conditions and describes how closures
adversely affect the functioning of Palestinian hospitals.16
Sustained military actions exacerbate these hardships. Following a vicious
wave of terror attacks against Israelis in March 2002 the Israeli Defense
Forces (IDF) systematically entered Palestinian cities to destroy terrorist infrastructures. The fighting in some areas was fierce, and it was soon apparent that
troops fired on ambulances and killed medical personnel. In the most serious
incidents, the director of the Red Crescent in Jenin, a medic, an ambulance
driver, and an UNRWA employee were killed by gunfire when their ambulances were attacked. The director of a Bethlehem hospital also died after he
was fired on by troops unaware that he had been authorized to collect medical
supplies. Intense fighting also impeded the timely evacuation of the wounded
and made access to medical care precarious. B’Tselem, The Public Committee
against Torture in Israel (PCATI), and Physicians for Human Rights (PHR)
document cases of hospitals blockaded and closed, of wounded who died
unable to reach medical facilities, and of dialysis patients and pregnant women
unable to receive treatment after being turned back at roadblocks and
checkpoints.17
Human rights organizations such as B’Tselem, PHR, and the ICRC call on
Israel to fulfill its obligations under international law which requires Israel, as
an occupying power, to safeguard access to medical facilities. As a party to an
armed conflict, Israel, like the Palestinians, must also respect the protected
status of medical personnel and medical facilities (Fourth Geneva Convention,
Articles 18, 20) and provide care for the wounded, the sick, the infirm, and
expectant mothers (Articles 16, 17).
In response to the charges leveled by Palestinians and by human rights
organizations, Israel invokes exceptions provided by international law together
with the more generalized defense of military necessity. International law
allows exceptions to the timely evacuation of the wounded if “military consid253
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erations do not enable medical teams to enter the area and evacuate the
wounded.” 18 Hospitals and ambulances lose their protected status if used for
hostile purposes (Article 19), and indeed Israeli officials documented several
cases of Palestinians using ambulances to transport terrorist personnel and
material. Although critics agree that this may necessitate careful searches of
ambulances, it cannot, in their opinion, justify indiscriminate attacks on medical personnel.
The argument from military necessity is less specific and more complicated.
To justify the blockades and subsequent distress caused to the Palestinian
civilian population, one must take the uneasy view that Israelis and Palestinians are engaged in a perpetual conflict without any well-defined goal or
criterion of successful conclusion. Although Israel is fighting both to end terror
and to bring the Palestinians back to the negotiating table, it is terror —
indiscriminate and brutal attacks on innocent civilians — that is the chief concern. Suppressing terror is Israel’s sole military goal, but it is not one that is
easily quantified or measured. Because this goal is indeterminate and interminable, Israel finds that it is necessary to curtail the movement of most
civilians and sometimes obstruct access to medical care to contain terror.
But one must be careful about pushing these arguments too far. Although
sieges, blockades, and attacks on ambulances are sometimes necessary to fight
terror, exceptions to international law and claims of military necessity cannot
underwrite a sweeping norm of unacceptable behavior. Instead, they can only
offer grounds for infrequent exceptions to internationally accepted rules and
practices. This point is often overlooked. As the current conflict drags into its
third year, medical care remains impeded and medical personnel are vulnerable
to the dangers of armed conflict. Although terrorism and the fight against
terrorism take a heavy toll on both sides, Israelis, particularly those in the
medical profession, must be vigilant and vocal about maintaining the protections due civilians, noncombatant medical personnel, and the wounded.
Conclusion
A conflict of local and universal norms underscores many of the bioethical
dilemmas facing Israel today. Traditional values, a strong sense of community,
and national interests square off against universal humanitarian norms ranging
from respect for dignity to noncombatant immunity. Israel is not a liberal state
forged entirely in the Western mold, and its attempts to fuse disparate values
will serve emerging nations struggling to embrace democratic norms as well as
those more established nations coming to grips with parochial interests and
traditional values.
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